Overview

On 20 September 2007, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Mylotarg 5 mg powder for solution for infusion, intended for the treatment of acute myeloid leukaemia. The company that applied for authorisation is Wyeth Europa Ltd. The applicant requested a re-examination of the opin ion. After having considered the grounds for this request, the CHMP re-examined the initial opinion , and confirmed the refusal of the marketing authorisation on 24 January 2008.

Questions and answers on the recommendation for the refusal of the marketing authorization for Mylotarg

български (BG) (181.19 KB - PDF)
español (ES) (34.57 KB - PDF)
čeština (CS) (139.98 KB - PDF)
dansk (DA) (34.62 KB - PDF)
Deutsch (DE) (34.76 KB - PDF)
eesti keel (ET) (33.7 KB - PDF)
ελληνικά (EL) (180.22 KB - PDF)
français (FR) (34.13 KB - PDF)
italiano (IT) (34.23 KB - PDF)
latviešu valoda (LV) (146.46 KB - PDF)
lietuvių kalba (LT) (117.91 KB - PDF)
magyar (HU) (115.28 KB - PDF)
Malti (MT) (157.27 KB - PDF)
Nederlands (NL) (34.13 KB - PDF)
polski (PL) (123.87 KB - PDF)
português (PT) (32.9 KB - PDF)
română (RO) (149.11 KB - PDF)
slovenčina (SK) (121.71 KB - PDF)
slovenščina (SL) (113.35 KB - PDF)
Suomi (FI) (33.39 KB - PDF)
svenska (SV) (34.15 KB - PDF)

Product details

Name of medicine
Mylotarg
Active substance
gemtuzumab ozogamicin
International non-proprietary name (INN) or common name
gemtuzumab ozogamicin
Therapeutic area (MeSH)
Leukemia, Myeloid, Acute
Anatomical therapeutic chemical (ATC) code
L01XC05

Pharmacotherapeutic group

Antineoplastic agents

Application details

EMA product number
EMEA/H/C/000705

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Marketing authorisation applicant
Wyeth Europa Ltd
Opinion adopted
24/01/2008
Refusal of marketing authorisation
14/04/2008

Assessment history

Mylotarg : EPAR - Refusal public assessment report

This page was last updated on

How useful do you find this page?